Evidence map›Paper›PMID 41716960›Full record

ArticleMedComm2026

Spironolactone and Fibrosis in Heart Failure Risk: Machine Learning Analysis of HOMAGE Trial Plasma Proteomics.

Susana Ravassa, Nicolas Girerd, Frank Edelman, Begoña López, João Pedro Ferreira, Daniela Zurkan, Gorka San José, Iñigo Latasa, Pierpaolo Pellicori, Franco Cosmi and 11 more

Abstract read
In one paragraph

Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. The Role of Thrombospondin-2 in Myocardial Fibrosis.Drug design, development and therapy · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Susana RavassaLaboratory of Heart Failure CIMA Universidad de Navarra and IdiSNA Pamplona Spain.ORCID https://orcid.org/0000-0001-5926-5677
Nicolas GirerdInserm, Centre d'Investigation Clinique Plurithématique 1433, U1116, CHRU De Nancy, F-CRIN INI-CRCT Université De Lorraine Nancy France.
Frank EdelmanDepartment of Internal Medicine and Cardiology Campus Virchow Klinikum Charité University Medicine Berlin, Germany.
Begoña LópezLaboratory of Heart Failure CIMA Universidad de Navarra and IdiSNA Pamplona Spain.
João Pedro FerreiraInserm, Centre d'Investigation Clinique Plurithématique 1433, U1116, CHRU De Nancy, F-CRIN INI-CRCT Université De Lorraine Nancy France.
Daniela ZurkanDepartment of Internal Medicine and Cardiology Campus Virchow Klinikum Charité University Medicine Berlin, Germany.
Gorka San JoséLaboratory of Heart Failure CIMA Universidad de Navarra and IdiSNA Pamplona Spain.
Iñigo LatasaLaboratory of Heart Failure CIMA Universidad de Navarra and IdiSNA Pamplona Spain.
Pierpaolo PellicoriSchool of Cardiovascular and Metabolic Health University of Glasgow Glasgow UK.
Franco CosmiDepartment of Cardiology Cortona Hospital Arezzo Italy.
Johannes PetutschniggDZHK (German Centre for Cardiovascular Research), Partner Site Berlin Berlin Germany.
Stephane HeymansDepartment of Cardiology Maastricht University Medical Center Maastricht the Netherlands.
Hans-Peter Brunner-La RoccaDepartment of Cardiology Maastricht University Medical Center Maastricht the Netherlands.
Burkert PieskeDivision of Cardiology, Department of Internal Medicine University Medicine Rostock Rostock Germany.
Christian DellesSchool of Cardiovascular and Metabolic Health University of Glasgow Glasgow UK.
Andrew L ClarkCastle Hill Hospital Hull University Teaching Hospitals NHS Trust Cottingham UK.
Javier DíezLaboratory of Heart Failure CIMA Universidad de Navarra and IdiSNA Pamplona Spain.
Faiez ZannadInserm, Centre d'Investigation Clinique Plurithématique 1433, U1116, CHRU De Nancy, F-CRIN INI-CRCT Université De Lorraine Nancy France.
John G F ClelandSchool of Cardiovascular and Metabolic Health University of Glasgow Glasgow UK.
Arantxa GonzálezLaboratory of Heart Failure CIMA Universidad de Navarra and IdiSNA Pamplona Spain.
HOMAGE Trial Committees and Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the HOMAGE (Heart Omics in AGEing) trial, spironolactone reduced serum concentrations of procollagen Type I C-terminal propeptide (PICP), a fibrosis biomarker, in patients at risk of heart failure. To elucidate the underlying mechanisms, multidimensional analyses including proteomics were conducted. Olink cardiovascular and inflammation panels (

Indexed as

biomarkersfibrosisheart failuremachine learning algorithms (MLA)procollagen Type I C‐terminal propeptide (PICP)spironolactone

Identifiers

PMID41716960
PMCPMC12914075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.